Jim Cramer on Vanda Pharmaceuticals: “I’m Going to Bless That One as Your Spec”

Group 1 - Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is recognized as a speculative investment opportunity by Jim Cramer, who suggests it can be considered a "spec" stock [1] - The company focuses on developing therapies for sleep, neurological, psychiatric, and inflammatory disorders [1] - On August 28, Vanda announced that the U.S. FDA granted Orphan Drug Designation for VGT-1849B, a selective JAK2 inhibitor aimed at treating polycythemia vera, a rare blood disorder characterized by excessive red blood cell production [1] Group 2 - The article suggests that while VNDA has potential, certain AI stocks may offer greater upside potential and lower downside risk [2]